Management will first participate in the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 9 at 8:00 a.m. ET. Shortly thereafter, the team moves to the 24th Annual Morgan Stanley Global Healthcare Conference on September 14, with a presentation scheduled for 2:35 p.m. ET.

Investors and interested stakeholders can monitor both sessions through live webcasts hosted on the company's investor relations portal. Each event recording will remain available for public viewing for 30 days. Insmed currently focuses its drug development efforts across three core pillars: respiratory conditions, immunology and inflammation, and neuro-rare diseases.